Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01893372 · ClinicalTrials.gov registry record · Phase 2
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT01893372: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01893372 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01893372, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if eltrombopag can help to control MDS. The safety of this drug will also be studied.
Primary Outcome
Overall response rate (ORR) based on the International Working Group (IWG)-2006 criteria, which include complete remission (CR), partial remission (PR), and major hematologic improvement (HI). Patients' overall response assessed after at least 2 cycles of treatment and no more than after 6 cycles of treatment and each cycle is 28 days. CR is Bone marrow of \</= 5% myeloblasts with normal maturation of cell lines, persistent dysplasia and a hemoglobin \>/= 11g/dl, platelets \>/= 100x10\^9/L, neut
Interventions
- DRUG Eltrombopag
- DRUG Hypomethylating Agent (HMA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2013-10 |
| Est. Completion | 2019-01-06 |
| Phase | Phase 2 |
What the finished NCT01893372 record still lists
NCT01893372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Eltrombopag is the first listed.
NCT01893372 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01893372 about?
NCT01893372 is a clinical study titled "Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)". The goal of this clinical research study is to learn if eltrombopag can help to control MDS. The safety of this drug will also be studied.
What is the current status of trial NCT01893372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2013-10. Estimated completion is 2019-01-06.
What interventions are being tested in trial NCT01893372?
The interventions under investigation include: Eltrombopag (DRUG), Hypomethylating Agent (HMA) (DRUG).
Who is sponsoring clinical trial NCT01893372?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01893372's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia